Lipophilic index of serum phospholipids in patients with type 2 diabetes and atherosclerotic cardiovascular disease: links with metabolic control, vascular inflammation and platelet activation | springermedicine.com

Springer Medicine

Top

Cardiovascular Diabetology

Published in:

Open Access 01-12-2024 | Research

Lipophilic index of serum phospholipids in patients with type 2 diabetes and atherosclerotic cardiovascular disease: links with metabolic control, vascular inflammation and platelet activation

Authors: Paweł Rostoff, Dominika Drwiła-Stec, Anna Majda, Konrad Stępień, Jadwiga Nessler, Grzegorz Gajos

Published in: Cardiovascular Diabetology | Issue 1/2024

Login to get access

Abstract

Background

Little is known about the mechanisms underlying the association of the serum phospholipid lipophilic index (LI) with atherosclerotic cardiovascular disease (ASCVD) in patients with type 2 diabetes (T2D). Therefore, we investigated whether the LI is associated with glucometabolic control, meta-inflammation, thrombin generation, fibrin clot properties, endothelial function and platelet activation in T2D patients with angiographically documented ASCVD.

Methods

We studied 74 T2D patients with ASCVD, aged 65.6 ± 6.8 years, with a median diabetes duration of 10 years and median HbA1c of 7.0%. Serum phospholipid fatty acids (FAs) were measured by gas chromatography. The serum phospholipid LI was calculated as the sum of the products of the proportion (% of total FAs) with the melting points (°C) of each individual FA, divided by the sum of the proportions of all FAs. Levels of HbA1c, insulin, leptin, adiponectin, lipid profiles, inflammatory markers (hsCRP, interleukin-6, TNF-α), Lp-PLA₂ (a biomarker of vascular inflammation), endothelial function (sICAM-1, sVCAM-1, FMD, NMD), thrombin generation, fibrin clot properties and platelet activation, measured by light transmission aggregometry with arachidonic acid [AA] and adenosine diphosphate [ADP], were assessed.

Results

Patients with LI > 16.9 °C (median) had higher HbA1c concentrations by 5.9% compared to the remaining subjects (p = 0.035). In this group, HbA1c levels ≥ 7.0% were found more often than in individuals with LI ≤ 16.9 °C (62.2 vs. 35.1%; p = 0.020). Subjects with LI > 16.9 °C had higher levels of TCh by 17.1% (p = 0.012), LDL-Ch by 29.4% (p = 0.003), interleukin-6 by 22.2% (p = 0.031) and Lp-PLA₂ by 32.4% (p = 0.040), compared to the remaining patients. Moreover, they had increased maximal platelet aggregation induced by AA (p = 0.045), but not by ADP. Serum phospholipid LI correlated with HbA1c (r = 0.24; p = 0.037), TCh (r = 0.36; p = 0.002), LDL-Ch (r = 0.38; p < 0.001), interleukin-6 (r = 0.27; p = 0.020) and Lp-PLA₂ (r = 0.26; p = 0.026). There were no intergroup differences in endothelial function, thrombin generation and fibrin clot properties. Regression analysis showed that HbA1c ≥ 7.0% and serum levels of LDL-Ch, interleukin-6 and Lp-PLA₂ were predictors of LI > 16.9 °C in adjusted models.

Conclusions

In well-controlled T2D patients with ASCVD, the higher serum phospholipid LI is associated with worse glucometabolic control, enhanced vascular inflammation and higher platelet reactivity during aspirin treatment at cyclooxygenase-1-selective doses.

1.

Marx N, Federici M, Schütt K, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043–140. https://doi.org/10.1093/eurheartj/ehad192.CrossRefPubMed

2.

Pająk A, Jankowski P, Zdrojewski T. The burden of cardiovascular disease risk factors: a current problem. Kardiol Pol. 2022;80(1):5–15. https://doi.org/10.33963/KP.a2022.0018.CrossRefPubMed

3.

Satman I. Prediabetes and diabetes: main characteristics. Pol Arch Intern Med. 2023;133(3):16469. https://doi.org/10.20452/pamw.16469.CrossRefPubMed

4.

Wełnicki M, Gorczyca-Głowacka I, Mamcarz A, et al. The use of GLP-1 analogues in the treatment of diabetes in patients with cardiovascular diseases. The expert opinion of the Working Group of Cardiovascular Pharmacotherapy of the Polish Cardiac Society. Kardiol Pol. 2022;80(12):1286–9. https://doi.org/10.33963/KP.a2022.0282.CrossRefPubMed

5.

World Health Organization. (2024). Diabetes. https://www.who.int/health-topics/diabetes [Accessed August 1, 2024].

6.

International Diabetes Federation. IDF Diabetes Atlas. (2021). Diabetes around the world in 2021. https://diabetesatlas.org [Accessed August 1, 2024].

7.

Pérez-Hernández IH, Domínguez-Fuentes JM, Palomar-Morales M, et al. Liver mitochondrial membrane fluidity at early development of diabetes and its correlation with the respiration. J Bioenerg Biomembr. 2017;49(3):231–9. https://doi.org/10.1007/s10863-017-9700-5.CrossRefPubMed

8.

Zhang Y, Xia Z, Cai X, et al. Association of metabolic dysfunction-associated fatty liver disease with systemic atherosclerosis: a community-based cross-sectional study. Cardiovasc Diabetol. 2023;22(1):342. https://doi.org/10.1186/s12933-023-02083-0.CrossRefPubMedPubMedCentral

9.

Pilon M. Revisiting the membrane-centric view of diabetes. Lipids Health Dis. 2016;15(1):167. https://doi.org/10.1186/s12944-016-0342-0.CrossRefPubMedPubMedCentral

10.

Tsuda K, Nishio I. Insulin sensitivity, glucose metabolism, and membrane fluidity in hypertensive subjects. Circulation. 2004;109(20):e225. https://doi.org/10.1161/01.CIR.0000128536.99989.60.CrossRefPubMed

11.

Perona JS. Membrane lipid alterations in the metabolic syndrome and the role of dietary oils. Biochim Biophys Acta Biomembr. 2017;1690–703. https://doi.org/10.1016/j.bbamem.2017.04.015. 1859(9 Pt B).

12.

Tram L, Krogh Venø S, et al. Adipose tissue lipophilic index and risk of ischemic Stroke-A Danish case-cohort study. Nutrients. 2018;10(11):1570. https://doi.org/10.3390/nu10111570.CrossRefPubMedPubMedCentral

13.

Wygrecka M, Hadzic S, Potaczek DP, et al. Decoding the role of fatty acids and their metabolites in lung fibrosis. Pol Arch Intern Med. 2023;133(7–8):16520. https://doi.org/10.20452/pamw.16520.CrossRefPubMed

14.

Kröger J, Jacobs S, Jansen EH, et al. Erythrocyte membrane fatty acid fluidity and risk of type 2 diabetes in the EPIC-Potsdam study. Diabetologia. 2015;58(2):282–9. https://doi.org/10.1007/s00125-014-3421-7.CrossRefPubMed

15.

Toledo E, Campos H, Ding EL, et al. A novel fatty acid profile index–the lipophilic index–and risk of myocardial infarction. Am J Epidemiol. 2013;178(3):392–400. https://doi.org/10.1093/aje/kws476.CrossRefPubMedPubMedCentral

16.

Cooper GM. The cell: a molecular approach. 2nd edition. Sunderland (MA): Sinauer Associates; 2000. Structure of the Plasma Membrane. https://www.ncbi.nlm.nih.gov/books/NBK9898/

17.

Nieto-Garai JA, Lorizate M, Contreras FX. Shedding light on membrane rafts structure and dynamics in living cells. Biochim Biophys Acta Biomembr. 2022;1864(1):183813. https://doi.org/10.1016/j.bbamem.2021.183813.CrossRefPubMed

18.

Wu H, Ding EL, Toledo ET, et al. A novel fatty acid lipophilic index and risk of CHD in US men: the health professionals follow-up study. Br J Nutr. 2013;110(3):466–74. https://doi.org/10.1017/S0007114512005272.CrossRefPubMedPubMedCentral

19.

Liu Q, Lichtenstein AH, Matthan NR, et al. Higher lipophilic index indicates higher risk of coronary heart disease in postmenopausal women. Lipids. 2017;52(8):687–702. https://doi.org/10.1007/s11745-017-4276-8.CrossRefPubMedPubMedCentral

20.

Poreba M, Mostowik M, Siniarski A, et al. Treatment with high-dose n-3 PUFAs has no effect on platelet function, coagulation, metabolic status or inflammation in patients with atherosclerosis and type 2 diabetes. Cardiovasc Diabetol. 2017;16(1):50. https://doi.org/10.1186/s12933-017-0523-9.CrossRefPubMedPubMedCentral

21.

Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–77. https://doi.org/10.1093/eurheartj/ehz425.CrossRefPubMed

22.

Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40(3):237–69. https://doi.org/10.1093/eurheartj/ehy462.CrossRefPubMed

23.

Drwila D, Rostoff P, Nessler J, et al. Prognostic significance of atherogenic index of plasma, atherogenic coefficient and lipoprotein combined index among elderly patients with non-ST-segment elevation myocardial infarction in 1-year follow-up. Bratisl Lek Listy. 2022;123(12):872–7. https://doi.org/10.4149/BLL_2022_139.CrossRefPubMed

24.

Alifu J, Xiang L, Zhang W, et al. Association between the atherogenic index of plasma and adverse long-term prognosis in patients diagnosed with chronic coronary syndrome. Cardiovasc Diabetol. 2023;22(1):255. https://doi.org/10.1186/s12933-023-01989-z.CrossRefPubMedPubMedCentral

25.

Rostoff P, Frączek-Jucha M, Konduracka E, et al. Serum phospholipid cis-palmitoleic acid in patients with type 2 diabetes and chronic coronary syndrome: an assessment of the relationship with diabetes duration, systemic low-grade inflammation and circulating oxidized low-density lipoprotein. Kardiol Pol. 2020;78(6):584–7. https://doi.org/10.33963/KP.15285.CrossRefPubMed

26.

Chmiel J, Natorska J, Ząbczyk M, et al. Fibrin clot properties in coronary artery ectatic disease: pilot data from the CARE-ANEURYSM study. Kardiol Pol. 2023;81(11):1145–8. https://doi.org/10.33963/v.kp.96983.CrossRefPubMed

27.

Siniarski A, Haberka M, Mostowik M, et al. Treatment with omega-3 polyunsaturated fatty acids does not improve endothelial function in patients with type 2 diabetes and very high cardiovascular risk: a randomized, double-blind, placebo-controlled study (Omega-FMD). Atherosclerosis. 2018;271:148–55. https://doi.org/10.1016/j.atherosclerosis.2018.02.030.CrossRefPubMed

28.

Xu H, Ärnlöv J, Sandhagen B, et al. Lipophilic index, kidney function, and kidney function decline. Nutr Metab Cardiovasc Dis. 2016;26(12):1096–103. https://doi.org/10.1016/j.numecd.2016.09.006.CrossRefPubMed

29.

de Lange Z, Kahler B, Smuts CM, et al. Plasma phospholipid fatty acids are associated with altered fibrin clot properties in a population-based setting. Prostaglandins Leukot Essent Fat Acids. 2019;143:1–7. https://doi.org/10.1016/j.plefa.2019.02.001.CrossRef

30.

Matthan NR, Ip B, Resteghini N, et al. Long-term fatty acid stability in human serum cholesteryl ester, triglyceride, and phospholipid fractions. J Lipid Res. 2010;51(9):2826–32. https://doi.org/10.1194/jlr.D007534.CrossRefPubMedPubMedCentral

31.

Karlsson M, Mårild S, Brandberg J, et al. Serum phospholipid fatty acids, adipose tissue, and metabolic markers in obese adolescents. Obes (Silver Spring). 2006;14(11):1931–9. https://doi.org/10.1038/oby.2006.225.CrossRef

32.

Glew RH, Casados JK, Huang YS, et al. The fatty acid composition of the serum phospholipids of children with sickle cell disease in Nigeria. Prostaglandins Leukot Essent Fat Acids. 2002;67(4):217–22. https://doi.org/10.1054/plef.2002.0423.CrossRef

33.

Kałużna-Czaplińska J. Current medical research with the application of coupled techniques with mass spectrometry. Med Sci Monit. 2011;17(5):RA117–23. https://doi.org/10.12659/msm.881756.CrossRefPubMedPubMedCentral

34.

Fialkov AB, Lehotay SJ, Amirav A. Less than one minute low-pressure gas chromatography - mass spectrometry. J Chromatogr A. 2020;1612:460691. https://doi.org/10.1016/j.chroma.2019.460691.CrossRefPubMed

35.

Tibori K, Orosz G, Zámbó V, et al. Molecular mechanisms underlying the elevated expression of a potentially type 2 diabetes Mellitus Associated SCD1 variant. Int J Mol Sci. 2022;23(11):6221. https://doi.org/10.3390/ijms23116221.CrossRefPubMedPubMedCentral

36.

Sun Q, Xing X, Wang H, et al. SCD1 is the critical signaling hub to mediate metabolic diseases: mechanism and the development of its inhibitors. Biomed Pharmacother. 2024;170:115586. https://doi.org/10.1016/j.biopha.2023.115586.CrossRefPubMed

37.

Lyytinen AT, Yesmean M, Manninen S, et al. Fatty fish consumption reduces lipophilic index in erythrocyte membranes and serum phospholipids. Nutr Metab Cardiovasc Dis. 2023;33(7):1453–60. https://doi.org/10.1016/j.numecd.2023.04.011.CrossRefPubMed

38.

Soltani N, Farhangi MA, Nikniaz L, et al. Association between a novel dietary lipophilic index (LI) with metabolic phenotypes in a community-based study in Tabriz- Iran. BMC Endocr Disord. 2020;20(1):159. https://doi.org/10.1186/s12902-020-00638-w.CrossRefPubMedPubMedCentral

39.

Russell J, Du Toit EF, Peart JN, et al. Myocyte membrane and microdomain modifications in diabetes: determinants of ischemic tolerance and cardioprotection. Cardiovasc Diabetol. 2017;16(1):155. https://doi.org/10.1186/s12933-017-0638-z.CrossRefPubMedPubMedCentral

40.

Poreba M, Rostoff P, Siniarski A, et al. Relationship between polyunsaturated fatty acid composition in serum phospholipids, systemic low-grade inflammation, and glycemic control in patients with type 2 diabetes and atherosclerotic cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):29. https://doi.org/10.1186/s12933-018-0672-5.CrossRefPubMedPubMedCentral

41.

Kadoglou NP, Khattab E, Velidakis N, et al. A new approach of statin therapy in carotid atherosclerosis: targeting indices of plaque vulnerability on the top of lipid-lowering. A narrative review. Kardiol Pol. 2022;80(9):880–90. https://doi.org/10.33963/KP.a2022.0155.CrossRefPubMed

42.

Szczeklik W, Sanak M, Rostoff P, et al. Common polymorphisms of cyclooxygenase-2 and prostaglandin E2 receptor and increased risk for acute coronary syndrome in coronary artery disease. Thromb Haemost. 2008;100(5):893–8.CrossRefPubMed

43.

Lv Y, Li K, Wang S, et al. Protective role of arachidonic acid against diabetic myocardial ischemic injury: a translational study of pigs, rats, and humans. Cardiovasc Diabetol. 2024;23(1):58. https://doi.org/10.1186/s12933-024-02123-3.CrossRefPubMedPubMedCentral

44.

Li C, Chen H. Role of arachidonic acid in ischemic heart disease under different comorbidities: Risk or protection? Cardiovasc Diabetol. 2024;23(1):218. https://doi.org/10.1186/s12933-024-02277-0.CrossRefPubMedPubMedCentral

45.

Kakouros N, Rade JJ, Kourliouros A, et al. Platelet function in patients with diabetes Mellitus: from a theoretical to a practical perspective. Int J Endocrinol. 2011;2011:742719. https://doi.org/10.1155/2011/742719.CrossRefPubMedPubMedCentral

46.

Watala C, Gwoździński K, Pluskota E, et al. Diabetes mellitus alters the effect of peptide and protein ligands on membrane fluidity of blood platelets. Thromb Haemost. 1996;75(1):147–53.CrossRefPubMed

47.

Prisco D, Paniccia R, Bandinelli B, et al. Relationship between plasma and platelet phospholipid fatty acid composition in healthy subjects. Platelets. 1996;7(1–2):69–73. https://doi.org/10.3109/09537109609079512.CrossRefPubMed

48.

Jeon KH, Jeong YH, Chae IH, et al. Implication of diabetic status on platelet reactivity and clinical outcomes after drug-eluting stent implantation: results from the PTRG-DES consortium. Cardiovasc Diabetol. 2023;22(1):245. https://doi.org/10.1186/s12933-023-01976-4.CrossRefPubMedPubMedCentral

49.

Barrachina MN, Pernes G, Becker IC et al. Efficient megakaryopoiesis and platelet production require phospholipid remodeling and PUFA uptake through CD36. bioRxiv [Preprint]. 2023 Feb 12:2023.02.12.527706. https://doi.org/10.1101/2023.02.12.527706

50.

Marjan MN, Hamzeh MT, Rahman E, et al. A computational prospect to aspirin side effects: aspirin and COX-1 interaction analysis based on non-synonymous SNPs. Comput Biol Chem. 2014;51:57–62. https://doi.org/10.1016/j.compbiolchem.2014.05.002.CrossRefPubMed

51.

Bryk-Wiązania AH, Undas A. Hypofibrinolysis in type 2 diabetes and its clinical implications: from mechanisms to pharmacological modulation. Cardiovasc Diabetol. 2021;20(1):191. https://doi.org/10.1186/s12933-021-01372-w.CrossRefPubMedPubMedCentral

52.

Pretorius E. Platelets as Potent Signaling entities in type 2 diabetes Mellitus. Trends Endocrinol Metab. 2019;30(8):532–45. https://doi.org/10.1016/j.tem.2019.05.003.CrossRefPubMed

53.

An Y, Xu BT, Wan SR, et al. The role of oxidative stress in diabetes mellitus-induced vascular endothelial dysfunction. Cardiovasc Diabetol. 2023;22(1):237. https://doi.org/10.1186/s12933-023-01965-7.CrossRefPubMedPubMedCentral

Title: Lipophilic index of serum phospholipids in patients with type 2 diabetes and atherosclerotic cardiovascular disease: links with metabolic control, vascular inflammation and platelet activation
Authors: Paweł Rostoff
Dominika Drwiła-Stec
Anna Majda
Konrad Stępień
Jadwiga Nessler
Grzegorz Gajos
Publication date: 01-12-2024
Publisher: BioMed Central
Published in: Cardiovascular Diabetology / Issue 1/2024
Electronic ISSN: 1475-2840
DOI: https://doi.org/10.1186/s12933-024-02506-6

Other articles of this Issue 1/2024

Circulating total and H-specific GDF15 levels are elevated in subjects with MASLD but not in hyperlipidemic but otherwise metabolically healthy subjects with obesity

Open Access
Obesity
Original Research

Association of the triglyceride-glucose index with early-onset atherosclerotic cardiovascular disease events and all-cause mortality: a prospective cohort study

Open Access
Myocardial Infarction
Original Research

Relationships between ankle blood pressure indices and major adverse cardiovascular events in people with and without type 2 diabetes

Open Access
Type 2 Diabetes
Original Research

Association of triglyceride-glucose index with the risk of incident aortic dissection and aneurysm: a large-scale prospective cohort study in UK Biobank

Open Access
Aortic Aneurysm
Original Research

Relationship between changes in the triglyceride glucose-body mass index and frail development trajectory and incidence in middle-aged and elderly individuals: a national cohort study

Open Access
Original Research

Independent association of thigh muscle fat density with vascular events in Korean adults

Open Access
Arterial Diseases
Original Research

Keynote series | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Register your interest now

Keynote webinar | Spotlight on adolescent vaping

Live
Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET

Prof. Ann McNeill

Dr. Debbie Robson

Benji Horwell

Developed by: Springer Medicine

Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty in Geriatric Patients
On-demand webinar

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft

Prof. Barbara C. van Munster

Prof. Mirko Petrovic

Developed by: Springer Medicine

Watch now

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Read more

Home
Congress Coverage
- ESMO 2024
- ERS 2024
- EASD 2024
- ESC 2024
- EAN 2024
- ASCO 2024
- ACC 2024
Clinical Collections
- Advances in Alzheimer’s
About Springer Medicine
Key Specialties